These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 26840621)
21. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339 [TBL] [Abstract][Full Text] [Related]
22. NF2 Gene Participates in Regulation of the Cell Cycle of Meningiomas by Restoring Spindle Assembly Checkpoint Function and Inhibiting the Binding of Cdc20 Protein to Anaphase Promoting Complex/Cyclosome. Ma M; Ge Y; Zhang T World Neurosurg; 2022 Feb; 158():e245-e255. PubMed ID: 34728400 [TBL] [Abstract][Full Text] [Related]
24. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas. Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669 [TBL] [Abstract][Full Text] [Related]
25. Familial meningioma is not allelic to neurofibromatosis 2. Pulst SM; Rouleau GA; Marineau C; Fain P; Sieb JP Neurology; 1993 Oct; 43(10):2096-8. PubMed ID: 8413972 [TBL] [Abstract][Full Text] [Related]
26. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. Buccoliero AM; Castiglione F; R Degl'Innocenti D; Gheri CF; Garbini F; Taddei A; Ammannati F; Mennonna P; Taddei GL Neuropathology; 2007 Feb; 27(1):36-42. PubMed ID: 17319281 [TBL] [Abstract][Full Text] [Related]
27. Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Sanson M; Marineau C; Desmaze C; Lutchman M; Ruttledge M; Baron C; Narod S; Delattre O; Lenoir G; Thomas G Hum Mol Genet; 1993 Aug; 2(8):1215-20. PubMed ID: 8401504 [TBL] [Abstract][Full Text] [Related]
28. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462 [TBL] [Abstract][Full Text] [Related]
29. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160 [TBL] [Abstract][Full Text] [Related]
30. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391 [TBL] [Abstract][Full Text] [Related]
31. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas. Kimura Y; Saya H; Nakao M Neuropathology; 2000 Sep; 20(3):153-60. PubMed ID: 11132929 [TBL] [Abstract][Full Text] [Related]
32. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Kalamarides M; Niwa-Kawakita M; Leblois H; Abramowski V; Perricaudet M; Janin A; Thomas G; Gutmann DH; Giovannini M Genes Dev; 2002 May; 16(9):1060-5. PubMed ID: 12000789 [TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902 [TBL] [Abstract][Full Text] [Related]
34. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness. Tanahashi K; Natsume A; Ohka F; Motomura K; Alim A; Tanaka I; Senga T; Harada I; Fukuyama R; Sumiyoshi N; Sekido Y; Wakabayashi T J Neuropathol Exp Neurol; 2015 Jul; 74(7):704-9. PubMed ID: 26049897 [TBL] [Abstract][Full Text] [Related]
35. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Ueki K; Wen-Bin C; Narita Y; Asai A; Kirino T Cancer Res; 1999 Dec; 59(23):5995-8. PubMed ID: 10606247 [TBL] [Abstract][Full Text] [Related]
36. DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. Kim H; Park J; Jung Y; Song SH; Han SW; Oh DY; Im SA; Bang YJ; Kim TY Int J Oncol; 2010 Jun; 36(6):1563-72. PubMed ID: 20428781 [TBL] [Abstract][Full Text] [Related]
37. Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas. Ma HS; Wang EL; Xu WF; Yamada S; Yoshimoto K; Qian ZR; Shi L; Liu LL; Li XH Med Sci Monit; 2018 Jul; 24():4841-4850. PubMed ID: 30002361 [TBL] [Abstract][Full Text] [Related]
38. NF2: the wizardry of merlin. Xiao GH; Chernoff J; Testa JR Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860 [TBL] [Abstract][Full Text] [Related]
39. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Cordova C; Kurz SC Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743 [TBL] [Abstract][Full Text] [Related]
40. Altered expression of beta-catenin/E-cadherin in meningiomas. Brunner EC; Romeike BF; Jung M; Comtesse N; Meese E Histopathology; 2006 Aug; 49(2):178-87. PubMed ID: 16879395 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]